Market closedNon-fractional
Dyne Therapeutics/DYN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Ticker
DYN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
143
Website
www.dyne-tx.com
DYN Metrics
BasicAdvanced
$4.2B
Market cap
-
P/E ratio
-$3.91
EPS
1.00
Beta
-
Dividend rate
Price and volume
Market cap
$4.2B
Beta
1
Financial strength
Current ratio
21.828
Quick ratio
20.281
Long term debt to equity
4.573
Total debt to equity
5.568
Management effectiveness
Return on assets (TTM)
-40.98%
Return on equity (TTM)
-71.50%
Valuation
Price to book
7.79
Price to tangible book (TTM)
7.79
Price to free cash flow (TTM)
-12.756
Growth
Earnings per share change (TTM)
17.57%
3-year earnings per share growth (CAGR)
10.06%
What the Analysts think about DYN
Analyst Ratings
Majority rating from 10 analysts.
DYN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$66M
-1.50%
Profit margin
0.00%
NaN%
DYN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.08
-$0.99
-$1.09
-$0.81
-
Expected
-$0.81
-$0.83
-$0.92
-$0.80
-$0.72
Surprise
33.75%
18.92%
18.91%
1.25%
-
DYN News
AllArticlesVideos
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
GlobeNewsWire·1 month ago
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
GlobeNewsWire·1 month ago
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dyne Therapeutics stock?
Dyne Therapeutics (DYN) has a market cap of $4.2B as of July 27, 2024.
What is the P/E ratio for Dyne Therapeutics stock?
The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of July 27, 2024.
Does Dyne Therapeutics stock pay dividends?
No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Dyne Therapeutics dividend payment date?
Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.
What is the beta indicator for Dyne Therapeutics?
Dyne Therapeutics (DYN) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Dyne Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.